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Abstract 1 
Background: The peptide hormone kisspeptin is essential for human reproduction, acting on 2 
the hypothalamus to stimulate gonadotrophin releasing hormone (GnRH) secretion. 3 
Kisspeptin is currently being evaluated as a novel therapeutic for women with infertility. 4 
However some animal studies suggest that kisspeptin may also stimulate growth hormone 5 
(GH), prolactin and thyroid stimulating hormone (TSH) secretion, with implications for its 6 
safety; no previous study has investigated whether kisspeptin stimulates these pituitary 7 
hormones in humans.  8 
Aim: To determine whether kisspeptin-54 modulates GH, prolactin and TSH secretion in 9 
healthy women.  10 
Design and participants: Prospective, single-blinded, placebo-controlled, one-way cross-11 
over study. Five healthy women received 7 days of twice-daily subcutaneous bolus vehicle 12 
(month 1) or 6.4nmol/kg kisspeptin-54 (month 2).  13 
Measurements: Serum samples were analysed post-hoc for GH, prolactin and TSH. 14 
Results: Mean serum GH, PRL and TSH did not change during the first 4h following 15 
kisspeptin-54 injection when compared with vehicle. The mean frequency or amplitude of 16 
GH pulses (which influence GH function) did not change acutely following kisspeptin-54 17 
injection when compared with vehicle. No chronic changes in serum GH, PRL or TSH were 18 
observed over the 7 day period of twice-daily kisspeptin-54 injections when compared with 19 
vehicle.  20 
Conclusion: While we cannot exclude any effect of kisspeptin-54 on GH, prolactin or TSH 21 
secretion, we observed no significant changes in these hormones at a dose of kisspeptin-54 22 
administration known to stimulate gonadotrophin secretion in a small study of healthy 23 
women. This data has important implications for the potential of kisspeptin to treat patients 24 
with infertility.  25 
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Introduction 1 
The kisspeptins are a group of arginine-phenylalanine amide peptide hormones named 2 
according to their amino acid length (1), which are released from specialized hypothalamic 3 
neurons and trigger the secretion of gonadotrophin releasing hormone (GnRH) (2). Kisspeptin 4 
is critical for reproductive function, since patients with genetic inactivation of kisspeptin or its 5 
receptor have pubertal failure and infertility (3). Exogenous kisspeptin potently stimulates the 6 
secretion of the pituitary gonadotrophin hormones, luteinising hormone (LH) and follicle 7 
stimulating hormone (FSH) in numerous mammalian species including rats (4), mice (5), 8 
sheep (6), cows (7), and monkeys (8). In keeping with these animal studies, we and other 9 
investigators have demonstrated that kisspeptin stimulates gonadotrophin secretion and LH 10 
pulsatility in healthy men, women, and patients with certain forms of infertility (9-16). 11 
Furthermore, clinical trials are underway, investigating the potential of the most common 12 
circulating isoform of kisspeptin, kisspeptin-54, to trigger oocyte maturation women during in 13 
vitro fertilisation treatment. It is therefore therapeutically important to determine whether 14 
kisspeptin-54 also has physiological effects on other endocrine axes in women. 15 
In addition to its role stimulating reproductive function, a number of animal studies suggest 16 
that kisspeptin may also stimulate the secretion of growth hormone (GH) and prolactin. The 17 
kisspeptin receptor is expressed in the pituitary gland, from where GH and prolactin are 18 
secreted (1). Kisspeptin-10 stimulates growth hormone (GH) and prolactin secretion from 19 
cultured anterior pituitary cells taken from 8 month old male calves (17). Kisspeptin-10 also 20 
stimulates GH secretion when incubated with pituitary cells of female baboons (18), and 21 
increases prolactin secretion when incubated with pituitary cells of male and female goldfish 22 
(19). Furthermore, intravenous bolus injection of kisspeptin-10 acutely increases circulating 23 
levels of GH in heifers (7), and intracerebroventricular bolus injection of kisspeptin-10 24 
acutely increases circulating prolactin in male and female rats (20). However, a number of 25 
other animal studies have failed to identify non-gonadotrophin secretory effects of kisspeptin 26 
on the pituitary gland. Circulating levels of GH, prolactin, and thyroid stimulating hormone 27 
(TSH) were unaltered following intravenous bolus administration of kisspeptin-10 to adult 28 
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male rhesus monkeys (21). Intravenous bolus injection of kisspeptin-10 had no effect on 1 
circulating GH in pre-pubertal gilts (22), cattle (23) or goats (24). The current animal 2 
literature therefore implies a possible role for kisspeptin to stimulate prolactin and GH 3 
secretion, but this remains controversial. No previous study has examined the effects of 4 
kisspeptin administration on non-reproductive pituitary hormone secretion in humans. 5 
Hypersecretion of GH, prolactin and TSH each have serious adverse health consequences for 6 
patients (25-28). It is therefore important to establish whether kisspeptin modulates GH, 7 
prolactin and TSH secretion in healthy female volunteers. We performed a post-hoc analysis 8 
of a prospective single-blinded placebo-controlled clinical study (13), to determine for the 9 
first time whether kisspeptin-54 modulates the secretion of GH, prolactin and TSH in healthy 10 
female volunteers, at a dose known to stimulate gonadotrophin secretion potently.   11 
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Methods 1 
Subjects 2 
This is a post-hoc analysis of a single-blinded, placebo-controlled, one-way crossover study 3 
designed to investigate the effects of twice-daily administration of kisspeptin-54 on 4 
reproductive hormone secretion in healthy women (13). Following ethical approval by the 5 
Hammersmith and Queen Charlotte’s and Chelsea Hospitals Research Ethics Committee 6 
(registration number: 05/Q0406/142), written informed consent was obtained from five 7 
subjects. This study was performed in accordance with the Declaration of Helsinki. Subjects 8 
had regular menstrual cycles, and were recruited as described previously
 
(age in years: 9 
31.6±2.6, range 24-37; weight in kg: 60.4±2.5, range 50.4-63.8) (13). 10 
  11 
Protocol 12 
During month 1 of the protocol, all subjects self-administered twice-daily subcutaneous 13 
injections of saline (vehicle) between days 7 and 14 of their menstrual cycle.  During month 2 14 
of the protocol, the same five healthy female subjects self-administered twice-daily 15 
subcutaneous injections of kisspeptin-54 (6.4nmol/kg; equivalent to 37mcg/kg) (13), between 16 
days 7 and 14 of their menstrual cycle. Day 1 of each month was defined as the first day of 17 
menstrual bleeding. Full details of the protocol have been previously published (13). Methods 18 
for self-injection of kisspeptin-54 are described previously (10, 11, 13). 19 
 20 
Study 1: Acute effects of vehicle or kisspeptin-54 on GH, prolactin and TSH: Subjects 21 
underwent blood sampling during the 4 hour period immediately following the first injection 22 
of the vehicle (menstrual day 7, month 1) or kisspeptin-54 (menstrual day 7, month 2) 23 
treatment period. Vehicle or kisspeptin-54 6.4nmol/kg was administered subcutaneously at 0 24 
minutes, and blood was sampled for serum GH, prolactin, TSH and plasma kisspeptin-IR at -25 
30, 0, 10, 20, 40, 60, 90, 120, 150, 180, 210 and 240 minutes. Results are presented for 4/5 26 
subjects, since insufficient sample volume was available to analyse the results of one subject. 27 
 28 
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Study 2: Effects of vehicle or kisspeptin-54 on GH pulsatility: Subjects underwent blood 1 
sampling during an 8 hour period on the fourth injection day of twice-daily vehicle or 2 
kisspeptin-54 treatment (i.e. during menstrual day 11). Blood samples were taken every 10 3 
minutes after subcutaneous injection of vehicle or kisspeptin-54 for 480 minutes and were 4 
analysed for serum levels of GH, prolactin and TSH. Results are presented for 5 subjects. 5 
 6 
Study 3: Chronic effects of twice-daily vehicle or kisspeptin-54 administration on GH, 7 
prolactin and TSH: Serum levels of GH, prolactin and TSH immediately before the first 8 
injection of vehicle or kisspeptin-54 (day 7 of the menstrual cycle) were compared with levels 9 
immediately before the final injection (day 14 of the menstrual cycle). Hormone levels were 10 
calculated as a mean level from two serum samples. Results are presented for 4/5 subjects, 11 
since insufficient sample volume was available to analyse the results of one subject. 12 
 13 
Analytical Methods 14 
Serum GH was assayed on the Immulite 2000XPi platform (Siemens, Germany), with inter 15 
and intra-assay coefficients of variation (CV) of 5% and 6% respectively. Serum PRL and 16 
TSH were assayed on the Architect ci8000SR platform, (Abbott Diagnostics, USA). The 17 
inter- and intra-assay CV for both the PRL and TSH assays is 5% respectively. Measurement 18 
of the GH, PRL and TSH analytes on these automated platforms is based upon solid-phase; 19 
two-site chemiluminescent immunometric assays (ICMAs). 20 
 21 
Data analysis 22 
Area under curve (AUC) levels of hormone secretion were calculated using Prism software 23 
(GraphPad Inc., Ja Jolla, CA, USA). GH pulses were defined as elevations in serum GH 24 
consisting of at least two measurements, one of which was at least 3-fold higher than the 25 
assay CV. All data are expressed as mean ± standard error of mean (SEM). Hormone profiles 26 
during 4 hour blood sampling studies were analysed using repeated measures 2-way ANOVA 27 
with Bonferonni post hoc correction. Pairs of means were analysed using two-tailed t-tests. In 28 
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all cases, P<0.05 was considered statistically significant.  1 
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Results 1 
Study 1: Acute effects of the first injection of vehicle or kisspeptin-54 on circulating kisspeptin 2 
immunoreactivity, GH, prolactin and TSH 3 
Blood sampling for plasma kisspeptin-54, serum GH, prolactin and TSH was performed 4 
during the first 4 hours immediately after the first subcutaneous bolus injection of vehicle or 5 
kisspeptin-54. Plasma levels of kisspeptin-IR were markedly increased following 6 
subcutaneous bolus injection of kisspeptin-54 (mean AUC plasma kisspeptin-IR during 4 7 
hours following injection in h.pmol/L: 1684 ± 164, vehicle; 375000 ± 47680, kisspeptin-54, 8 
P<0.001 vs. vehicle), and kisspeptin-54 significantly increased serum LH when compared 9 
with vehicle (mean AUC serum LH during 4 hours following injection in h.IU/L: -151.0 ± 10 
45.7, vehicle; 1102.0 ± 588.0, kisspeptin-54, P<0.05 vs. vehicle) (13). No significant changes 11 
in serum GH, prolactin and TSH were observed following subcutaneous bolus injection of 12 
kisspeptin-54, (mean AUC serum level during 4 hours following injection: 57 ± 26 h.mcg/L, 13 
GH post-vehicle; 111 ± 57 h.mcg/L, GH post-kisspeptin-54, P=0.51 vs. GH post-vehicle; 14 
41356 ± 6176 h.mIU/L, prolactin post-vehicle; 42868 ± 7175 h.mIU/L, prolactin post-15 
kisspeptin-54, P=0.78 vs. prolactin post-vehicle; 300 ± 68 h.mIU/mL, TSH post-vehicle; 326 16 
± 78 h.mIU/mL, TSH post-kisspeptin-54, P=0.49 vs. TSH post-vehicle) (Figure 1A-I). 17 
 18 
Study 2: Effects of vehicle or kisspeptin-54 on GH pulsatility: We then examined in more 19 
detail the acute effects of vehicle or kisspeptin-54 on GH secretion in the same healthy 20 
women, by performing frequent blood sampling every 10min for 8 hours immediately 21 
following injection of vehicle or kisspeptin-54, on the fourth day a twice-daily injection 22 
regime. The mean level of serum GH was not significantly altered by subcutaneous bolus 23 
injection of kisspeptin-54 when compared with vehicle (AUC serum level during 8 hours 24 
following injection in h.mcg/L: 507 ± 174, GH post-vehicle; 399 ± 61, GH post-kisspeptin-25 
54, P= 0.61 vs. GH post-vehicle) (Figure 2A-C). Furthermore, no significant change in the 26 
mean number or amplitude of GH pulses was observed (Figure 2D-G).  27 
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Study 3: Chronic effects of twice-daily vehicle or kisspeptin-54 administration on GH, 1 
prolactin and TSH:  2 
We finally examined whether a 7 day treatment course (between menstrual days 7 and 14) of 3 
twice-daily kisspeptin-54 injections altered serum levels of GH, prolactin and TSH in healthy 4 
women when compared with vehicle injections. Levels of serum GH were non-significantly 5 
higher on menstrual day 14 when compared with menstrual day 7, but no significant 6 
differences were observed between vehicle and kisspeptin-54 treatment groups (mean serum 7 
level of GH in mcg/L: 0.39± 0.10, vehicle day 7; 0.27± 0.07, kisspeptin-54 day 7, P= 0.64 vs. 8 
vehicle day 7; 1.02 ± 0.24, vehicle day 14; 0.72 ± 0.38, kisspeptin-54 day 14, P= 0.45 vs. 9 
vehicle day 14) (Figure 3A-B). Levels of serum prolactin and TSH were similar on menstrual 10 
day 14 when compared with menstrual day 7, and no significant differences were observed 11 
between vehicle and kisspeptin-54 treatment groups (Figure 3C-F). 12 
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Discussion 1 
Kisspeptin is a hypothalamic neuropeptide, which plays a pivotal role in human reproduction. 2 
Kisspeptin potently stimulates gonadotrophin secretion in humans, which could be used to 3 
treat patients with reproductive disorders. However, kisspeptin has been shown recently to 4 
modulate the secretion of the pituitary hormones, GH, TSH and prolactin, during in vitro and 5 
in vivo animal studies. It is clinically important to determine whether exogenous kisspeptin 6 
also modulates the secretion of non-gonadotrophin pituitary hormones in humans. We report 7 
for the first time that subcutaneous bolus injection of kisspeptin-54 does not modulate GH, 8 
prolactin or TSH secretion significantly in healthy women, using a dose known to stimulate 9 
gonadotrophin secretion potently. 10 
Excessive secretion of GH, TSH and prolactin are associated with a number of adverse health 11 
consequences. Increased circulating levels of GH are associated with hypertension, 12 
myocardial hypertrophy (25) and diabetes mellitus (26). Hyperprolactinaemia leads to 13 
galactorrhoea and infertility (27). Furthermore, TSH hyper-secretion has sympathomimetic 14 
actions leading to tachyarrhythmias, tremor, insomnia, and osteoporosis (28). A number of 15 
studies performed in animals have identified that kisspeptin stimulates GH and prolactin. 16 
Gutierrez-Pascual et al. demonstrated that kisspeptin-10 stimulates secretion of GH from rat 17 
pituitary cells in vitro in a dose-dependent manner (29). Kadokawa et al demonstrated that 18 
kisspeptin-10 increased prolactin release from bovine anterior pituitary cells by 23% (17). 19 
Yang et al. observed that incubation of goldfish pituitary cells with kisspeptin-10 stimulated 20 
secretion of both GH and prolactin (19). In vivo studies by Kadokawa et al. showed that 21 
circulating concentrations of GH acutely increased over 4-fold following IV administration of 22 
1mg kisspeptin-10 in pre-pubertal female cows. (7). Furthermore, Szawka et al. observed that 23 
intracerebroventricular bolus injection of 3nmol kisspeptin-10 acutely increased circulating 24 
prolactin levels over 2-fold in male and female rats (20). There is a paucity of data examining 25 
the effects of kisspeptin on TSH secretion, but Luque et al. observed no stimulation of TSH 26 
following incubation of female baboon pituitary cells with kisspeptin-10 (18). Although we 27 
have previously reported that kisspeptin-54 acutely stimulated LH in these healthy female 28 
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volunteers (13), we did not observe any acute or chronic changes in GH, prolactin or TSH 1 
secretion in the same subjects. 2 
It is interesting to consider why subcutaneous administration of kisspeptin-54 was not 3 
observed to significantly change the secretion of GH, prolactin and TSH significantly in 4 
healthy female participants. Firstly, it is important to recognise that this study was performed 5 
in a small number of subjects, which was neither designed nor statistically powered to 6 
exclude an effect of kisspeptin-54 on GH, prolactin or TSH secretion. For instance, the mean 7 
number of GH pulses during kisspeptin-54 administration was nearly two-fold, but non-8 
significantly, higher when compared with saline. This study therefore cannot exclude that 9 
kisspeptin-54 modulates secretion of any of these hormones; rather, it suggests that no 10 
obvious change in GH, prolactin or TSH secretion is observed at the dose of kisspeptin-54 11 
known to potently stimulate reproductive hormones in healthy women. Although the tested 12 
dose of kisspeptin-54 potently stimulated gonadotrophin secretion (13), we cannot exclude 13 
that a higher dose of kisspeptin-54 would have stimulated GH, prolactin or TSH secretion. 14 
Furthermore, although plasma kisspeptin immunoreactivity was markedly increased 15 
following subcutaneous injection of kisspeptin-54, we cannot exclude that an intravenous 16 
route of administration of kisspeptin-54 would have been more effective in stimulating GH, 17 
prolactin and TSH secretion. It is possible that sex steroids potentiate the stimulatory action 18 
of kisspeptin on GH and prolactin secretion in non-human mammals; plasma concentrations 19 
of GH were increased following peripheral administration of kisspeptin-10 to ovariectomised 20 
female cows, but only following oestradiol and/or progesterone supplementation (30). 21 
Furthermore, Szawka et al showed that intracerebroventricular administration of kisspeptin-22 
10 only stimulated prolactin secretion in ovariectomised rats if they were pre-treated with 23 
estradiol (20). In light of these observations, it is interesting to note that we examined the 24 
effects of exogenous kisspeptin-54 on GH and prolactin secretion in healthy female 25 
volunteers during day 7 and day 11 of the menstrual cycle, when serum oestradiol levels were 26 
approximately 300pmol/L and 800pmol/L, respectively. It is therefore unlikely that 27 
kisspeptin-54 failed to stimulate significant GH or prolactin secretion in female subjects due 28 
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to low circulating levels of oestradiol. Age may also play a role in modulating the effects of 1 
kisspeptin on GH secretion; kisspeptin has been shown to be more effective at stimulating GH 2 
in anterior pituitary cells from juvenile cows when compared with adult cows. It would 3 
therefore be interesting to study whether kisspeptin-54 stimulated GH secretion in children; 4 
observing such an affect might imply that kisspeptin has distinct, developmental effects on 5 
non-gonadotrophin pituitary function, which are subsequently lost during adulthood. 6 
All of the previous studies investigating the effects of kisspeptin on GH, PRL and TSH 7 
studied the decapeptide isoform, kisspeptin-10, whereas we studied the effects of the 54 8 
amino acid isoform, kisspeptin-54. Kisspeptin-10 is actually the fragment of kisspeptin-54 9 
needed for binding to the kisspeptin receptor, and for biological activity (1). We therefore 10 
cannot exclude that kisspeptin-10 would stimulate GH, PRL and TSH secretion more potently 11 
when compared with kisspeptin-54 in healthy women. However, we have previously 12 
demonstrated in healthy subjects that kisspeptin-54 has a longer plasma half-life (approx. 13 
27min) when compared with kisspeptin-10 (approx. 4min) (9, 12). Furthermore, levels of 14 
plasma kisspeptin immunoreactivity are over 15-fold higher following an injection of 15 
kisspeptin-54 when compared with an equimolar injection of kisspeptin-10 (12). We would 16 
therefore not expect kisspeptin-54 to be less potent in its biological actions when compared 17 
with kisspeptin-10. 18 
As expected, GH was secreted in discrete pulses in our healthy female subjects (31). It was 19 
therefore important to confirm that kisspeptin-54 did not modulate the secretory pattern of 20 
GH secretion over an 8 hour period, rather than merely assessing area under curve GH 21 
secretion. During these 8 hour blood sampling studies (study 2), subjects had already received 22 
three previous days of twice-daily kisspeptin-54 injections regime; we therefore cannot 23 
exclude that tachyphylaxis to the effects of kisspeptin-54 on pituitary hormone (GH, 24 
Prolactin, TSH) secretion may have occurred, as has been demonstrated previously in women 25 
with gonadotrophin secretion (10). However, none of the subjects had changes in GH, 26 
Prolactin or TSH in response to kisspeptin-54 on the first day of treatment (study 1), which 27 
suggests that tachyphylaxis did not contribute to our observations. 28 
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We observed that levels of serum GH levels were non-significantly higher during menstrual 1 
day 14 when compared with menstrual day 7, in both vehicle and kisspeptin-54 treatment 2 
groups. Higher levels of serum GH have been observed previously in women during the 3 
periovulatory phase when compared with early follicular phase of the menstrual cycle (32). 4 
Furthermore, oestrogen administration increases GH secretion in oestrogen-deficient women 5 
with Turner’s syndrome (33). During the current study, serum GH may have therefore been 6 
elevated on menstrual day 14 due to increased levels of circulating oestrogen. The mechanism 7 
by which oestrogen influences GH secretion is currently unclear (34). However, a study by 8 
Ovesen et al. suggests that the rate of pulsatile GH secretion and GH pulse frequency are both 9 
increased whereas basal GH secretion is unchanged during the periovulatory phase of 10 
menstrual cycle when compared with the early follicular phase in healthy young women (35). 11 
It is therefore possible that oestrogen may promote GH pulse generation within the 12 
hypothalamus. However, it is also possible that oestradiol acts indirectly on GH by 13 
influencing the production of IGF-1 in the liver (34). 14 
In summary, this study is the first to examine the acute and chronic effects of exogenous 15 
kisspeptin-54 on GH, prolactin and TSH secretion in healthy female volunteers. While we 16 
cannot exclude any effect of kisspeptin-54 on GH, prolactin or TSH secretion, we observed 17 
no significant changes in these hormones at a dose of kisspeptin-54 administration known to 18 
stimulate gonadotrophin secretion in a small study of healthy women. This data has important 19 
implications for the safety of kisspeptin-54 as a potential therapeutic for patients with 20 
reproductive disorders. 21 
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Figure Legends: 1 
Figure 1: Acute effects of the first injection of vehicle or kisspeptin-54 on GH, prolactin 2 
and TSH (study 1). 5 healthy women were given a subcutaneous bolus injection of vehicle 3 
(saline) on day 7 of their menstrual cycle (follicular phase) in month 1 and kisspeptin-54 4 
(6.4nmol/kg) in month 2 of the study. Frequent blood sampling was conducted for 4 hours 5 
after the injection for pituitary hormones and kisspeptin levels. Results are presented for only 6 
4 subjects, since insufficient sample volume was available to analyse the results of one 7 
subject. The hormone level results of all participants were collated for GH (A), PRL (D) and 8 
TSH (G). Grouped mean results for each time point of the 4 hour study following the 9 
subcutaneous injection of vehicle in month 1 and kisspeptin-54 in month 2 are shown for GH 10 
(B), PRL (E) and TSH (H). Individual results are shown for GH (C), PRL (F), and TSH (I). 11 
There was no significant difference in hormone levels between the vehicle and kisspeptin 12 
groups. Data presented as mean±SEM. 13 
 14 
Figure 2: The effects of vehicle or kisspeptin-54 on GH pulsatility. 5 healthy women were 15 
given twice daily subcutaneous injections of vehicle (saline) in month 1 and kisspeptin-54 16 
(6.4nmol/kg) in month 2 from day 7 of their menstrual cycle (follicular phase) for 4 days 17 
followed by frequent blood sampling for 8 hours. A: Grouped mean results for each time 18 
point of the 8 hour study following 4 days of twice daily subcutaneous injections of vehicle in 19 
month 1 and kisspeptin-54 in month 2. (B) Collated and (C) Individual GH results for all 20 
participants following vehicle injections in month 1 and kisspeptin injections in month 2. (D) 21 
Collated and (E) Individual number of GH pulses in the 8 hour period following a 22 
subcutaneous injection of vehicle and kisspeptin-54 collated for the five participants. Three 23 
participants had two GH pulses following vehicle and kisspeptin-54 injection (data points 24 
nudged for clarity) (F) Collated and (G) Individual amplitude of the GH pulses collated for 25 
the five participants. Data presented as mean±SEM.  26 
 27 
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Figure 3: Effects of chronic subcutaneous administration of vehicle or kisspeptin. 5 1 
healthy women received twice daily subcutaneous injections of vehicle (saline) from day 7 of 2 
their menstrual cycle (follicular phase) for 7 days in month 1 of the study. This was followed 3 
in month 2 by twice daily subcutaneous injections of kisspeptin-54 (6.4nmol/kg) from day 7 4 
to day 14 of their menstrual cycle. A blood sample was taken prior to the first subcutaneous 5 
injection of vehicle (month 1) and kisspeptin-54 (month 2) on day 7 of their menstrual cycle 6 
and again on day 14. This allowed direct comparison between baseline and after 7 days of 7 
twice daily injections of vehicle or kisspeptin. Results are presented for only 4 subjects, since 8 
insufficient sample volume was available to analyse the results of one subject. The results 9 
were collated for all participants and shown for GH (A), PRL (C) and TSH (E). Individual 10 
results for all participants are shown for GH (B), PRL (D), and TSH (F). There was no 11 
statistical difference comparing the vehicle and kisspeptin groups or between the day 7 and 14 12 
results. Data presented as mean±SEM.  13 
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